

	REC'D	1 9) /	APR	2005
--	-------	-----	-----	-----	------

WIPO PCT

PATENT COOPERATION TREATY POT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P22279PCAU	FOR FURTHER See Notification of Transmittal of International Preliminary ACTION Examination Report (Form PCT/IPEA/416).				
International Application No.	International Filing Da (day/month/year)	re Priority Date (day/month/year)			
PCT/AU2003/001713	22 December 2003	20 December 2002			
International Patent Classification (IPC) or	national classification ar	nd IPC			
Int. Cl. 7 A61K 6/083					
Applicant	4 -1				
NSI DENTAL PTY LIMITED e	taı				
1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.					
2. This REPORT consists of a total of 3	sheets, including this	cover sheet.			
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
These annexes consist of a total	of sheet(s).				
3. This report contains indications relating	g to the following items:				
I X Basis of the report					
II Priority					
III Non-establishment of op	III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
IV Lack of unity of invention	Lack of unity of invention				
V X Reasoned statement und citations and explanation	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
VI Certain documents cited	VI Certain documents cited				
. · VII Certain defects in the int	Certain defects in the international application				
VIII Certain observations on the international application					
Date of submission of the demand Date of completion of the report					
20 July 2004		6 April 2005			
Name and mailing address of the IPEA/AU		Authorized Officer			
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA					
E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929		S. Chew			
		Telephone No. (02) 6283 2248			

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU2003/001713

I.	Basis of the report				
1.					
	x the international application as originally filed.				
	the description, pages, as originally filed,	-			
	pages , filed with the demand,				
	pages, received on with the letter of				
	the claims, pages, as originally filed,				
	pages , as amended (together with any statement) under Article 19,				
	pages, filed with the demand,				
	pages, received on with the letter of				
	the drawings, pages, as originally filed,				
	pages, filed with the demand,	·			
	pages, received on with the letter of				
	the sequence listing part of the description:				
	pages , as originally filed				
	pages, filed with the demand				
	pages, received on with the letter of				
2.	With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language which is: the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).				
	the language of publication of the international application (under Rule 48.3(b)).				
		55.0			
	the language of the translation furnished for the purposes of international preliminary examination (under Rule and/or 55.3).	es 55.2			
3.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:				
	contained in the international application in written form.				
	filed together with the international application in computer readable form.				
	furnished subsequently to this Authority in written form.				
	furnished subsequently to this Authority in computer readable form.				
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.				
	The statement that the information recorded in computer readable form is identical to the written sequence list been furnished	ting has			
. 4.	The amendments have resulted in the cancellation of:	٠.			
	the description, pages				
	the claims, Nos.				
	the drawings, sheets/fig.				
5.	This report has been established as if (some of) the amendments had not been made, since they have been congo beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	sidered to			
•	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).				
**	Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report				

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU2003/001713

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement		
	Novelty (N)	Claims 3-6, 9-18	YES
		Claims 1, 2, 7 and 8	NO
	. Inventive step (IS)	Claims 3-6, 9-18	YES
		Claims 1, 2, 7 and 8	NO .
	Industrial applicability (IA)	Claims 1-18	YES
		Claims .	NO

2. Citations and explanations (Rule 70.7)

NOVELTY (N): Claims 1, 2, 7 and 8

- D1 EP 976386A
- D2 US 5133957 A
- D3 WO 1999/020227
- D4 US 5797749 A

Claim 1 is directed to a formulation which is characterised by the incorporation of at least one light curable monomer that forms a resilient polymer gel upon curing.

Claim 2 is directed to a dentine sensitivity reducing formulation that includes any light-cured, form-stable, resilient gel polymer.

D4 (US 5797749) has disclosed a formulation for desensitising teeth comprising 2-hydroxy ethylmethacrylate, which is one of the monomers used in the present application. It is also disclosed that the 2-hydroxy ethylmethacrylate polymerises readily in air. Although the citation did not mention the formation of a resilient polymer gel upon curing, I consider this feature to be inherent in the polymerised monomer.

I also consider the term "that forms a resilient polymer gel upon curing" to be non-limiting as it merely denotes that the monomer has the capability to form a resilient polymer gel upon curing.

Therefore claims 1, 2, 7-8 are not novel in the light of the disclosure of D4.

Claims 3-6 and 9-18 are novel and have an inventive step as none of the citations D1 - D3 disclose or fairly suggest all of the features of the claims.

INVENTIVE STEP (IS): Claims 1, 2, 7 and 8

As above.

INDUSTRIAL APPLICABILITY (IA): Claims 1-18

Claims 1-18 have industrial applicability.